IL-12 receptor pathway (recombinant IL-12 cytokine)

Class

Alum-anchored interleukin-12 (IL-12) intratumoral immunotherapy ("anchored immunotherapy" platform; ANK-101)

Pathway

IL-12-driven local anti-tumor immune activation

The IL-12 receptor pathway is a central node in the immune system's decision to mount a cell-mediated, or 'type 1,' response against abnormal tissue. Interleukin-12 (IL-12) is a signaling protein normally released by dendritic cells and macrophages; when it binds its receptor on T cells and natural killer (NK) cells, it drives them to mature into potent, interferon-gamma-producing effector cells capable of killing tumor cells directly or recruiting further immune attack. Because many solid tumors actively suppress this kind of inflammatory response, delivering additional IL-12 is a rational strategy to convert an immunologically 'cold' tumor into an active battleground for the immune system. Historically, giving IL-12 systemically produced severe, sometimes dangerous inflammatory side effects because the cytokine circulated throughout the body rather than acting only where cancer cells reside. The approach here anchors the IL-12 molecule to an aluminum-based carrier and injects it directly into the tumor, so that a strong local burst of immune activation can occur while limiting how much cytokine reaches the general circulation. This mechanism is broadly relevant to solid tumor immunotherapy, particularly for cancers that respond poorly to checkpoint inhibitors alone and require an additional signal to prime an anti-tumor immune response.